MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo

被引:329
作者
Liu, Bo [1 ]
Peng, Xiao-Chun [2 ]
Zheng, Xiao-Li [3 ]
Wang, Jun [4 ]
Qin, Yong-Wen [1 ]
机构
[1] ChangHai Hosp, Cardiovasc Dept, Shanghai 200433, Peoples R China
[2] Shanghai Sixth Peoples Hosp, Dept Orthopaed, Shanghai, Peoples R China
[3] Second Mil Med Univ, Sch Pharm, Dept Pharmaceut, Shanghai, Peoples R China
[4] Second Mil Med Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China
关键词
Lung cancer; miR-126; Vascular endothelial growth factor; Gene therapy; PROGNOSTIC VALUE; MICRORNAS; EXPRESSION; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; RECEPTORS; FLT-1;
D O I
10.1016/j.lungcan.2009.01.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis, and its expression is up-regulated in manycarcinomas. In the present study, we found that a microRNA miR-126 has a binding site in 3'-untranslated region of the VEGF-A mRNA. In eight lung cancer cell lines, expression of miR-126 was down-regulated. Reporter gene assay showed that the co-transfection of mir-126 expression vector with pLuc-VEGF/mir126BS could reduce the activity of luciferase. Transfection experiments showed that miR-126 could decrease the expression of VEGF-A. Three human lung carcinoma cell lines A549, Y-90 and SPC-A1 were investigated as cancer models in vitro, and A549 infected by lentivirus-miR-126 (LV-miR-126) was studied in tumor xenograft model. Infection of LV-miR-126 can down-regulate the expression of VEGF-A in A549, Y-90 and SPC-A1 cell lines and can inhibit the growth of these cells. In addition, flow cytometry analysis revealed that LV-miR-126 infection can induce cell cycle G1 arrest in A549, Y-90 and SPC-A1 cells. Furthermore, in nude mice, the average weight of A549 tumor nodules in experimental group was reduced from 0.8035 +/- 0.1521 to 0.6235 +/- 0.0757 g, with the inhibitive rate being 22.4%. All these results revealed that miR-126 may have a tumor suppressor function in lung cancer cells and could be a promising treatment in anticancer therapy. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 21 条
[1]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[2]  
CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
[3]   The widespread impact of mammalian microRNAs on mRNA repression and evolution [J].
Farh, KKH ;
Grimson, A ;
Jan, C ;
Lewis, BP ;
Johnston, WK ;
Lim, LP ;
Burge, CB ;
Bartel, DP .
SCIENCE, 2005, 310 (5755) :1817-1821
[4]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[5]   The small RNA world [J].
Finnegan, EJ ;
Matzke, MA .
JOURNAL OF CELL SCIENCE, 2003, 116 (23) :4689-4693
[6]   Micrornas: Small RNAs with a big role in gene regulation [J].
He, L ;
Hannon, GJ .
NATURE REVIEWS GENETICS, 2004, 5 (07) :522-531
[7]   Involvement of MicroRNA in AU-rich element-mediated mRNA instability [J].
Jing, Q ;
Huang, S ;
Guth, S ;
Zarubin, T ;
Motoyama, A ;
Chen, JM ;
Di Padova, F ;
Lin, SC ;
Gram, H ;
Han, JH .
CELL, 2005, 120 (05) :623-634
[8]   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].
Johnson, DH ;
Fehrenbacher, L ;
Novotny, WF ;
Herbst, RS ;
Nemunaitis, JJ ;
Jablons, DM ;
Langer, CJ ;
DeVore, RF ;
Gaudreault, J ;
Damico, LA ;
Holmgren, E ;
Kabbinavar, F .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191
[9]   Encountering microRNAs in cell fate signaling [J].
Karp, X ;
Ambros, V .
SCIENCE, 2005, 310 (5752) :1288-1289
[10]   Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors [J].
Kuenen, BC ;
Rosen, L ;
Smit, EF ;
Parson, MRN ;
Levi, M ;
Ruijter, R ;
Huisman, H ;
Kedde, MA ;
Noordhuis, P ;
van der Vijgh, WJF ;
Peters, GJ ;
Cropp, GF ;
Scigalla, P ;
Hoekman, K ;
Pinedo, HM ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1657-1667